Abstract
Suzetrigine (VX-548), 2-pyridinecarboxamide, 4-[[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-, or 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide, is a selective voltage-gated sodium channel Na(V)1.8 blocker that was recently approved by FDA as a non-opioid analgesic to treat moderate to severe acute pain. It has a molecular formula C(21)H(20)F(5)N(3)O(4) and a molecular weight of 473.4 g/mol. The molecule has a chiral tetrahydrofuran core (2R,3S,4S,5R) that is conjugated to a picolinamide ring via an amide linker at position 2, a 3,4-difluoro-2-methoxyphenyl group at position 3, a methyl group at position 4, and both a trifluoromethyl group and a methyl group at position 5.